Table 3.
Characteristica | Unique and clustered strains |
Clustered vs unique |
|||||
---|---|---|---|---|---|---|---|
Unique (n = 168) |
Clustered (n = 97) |
Crude OR (95% CI) | Adjusted OR (95% CI) | P | |||
No. | % | No. | % | ||||
Sex | |||||||
Female | 68 | 40.5 | 33 | 34.0 | 1.00 (reference) | 1.00 | 0.53 |
Male | 100 | 59.5 | 64 | 66.0 | 1.32 (0.76–2.30) | 1.20 (0.68–2.14) | |
Age group (yr) | |||||||
0–29 | 36 | 21.4 | 27 | 27.8 | 1.00 | 1.00 | 0.64 |
30–44 | 37 | 22.0 | 18 | 18.6 | 0.65 (0.31–1.38) | 0.76 (0.32–1.80) | |
45–64 | 49 | 29.2 | 30 | 30.9 | 0.82 (0.42–1.60) | 0.85 (0.39–1.82) | |
>65 | 46 | 27.4 | 22 | 22.7 | 0.64 (0.31–1.30) | 0.60 (0.24–1.49) | |
Country of origin | |||||||
Foreign born | 121 | 72.0 | 55 | 56.7 | 1.00 | 1.00 | <0.01 |
US born | 47 | 28.0 | 42 | 43.3 | 1.97 (1.12–3.43) | 5.54 (2.25–13.65) | |
Race/ethnicity | |||||||
Black | 37 | 22.0 | 7 | 7.2 | 1.00 | 1.00 | <0.01 |
White | 50 | 29.8 | 37 | 38.1 | 3.91 (1.57–9.74) | 3.35 (1.20–9.33) | |
Hispanic | 41 | 24.4 | 33 | 34.0 | 4.25 (1.68–10.77) | 8.58 (2.97–24.75) | |
Asian/Pacific Islander | 39 | 23.2 | 20 | 20.6 | 2.71 (1.03–7.16) | 6.00 (1.98–18.18) | |
Medical insurance | |||||||
No | 51 | 30.4 | 41 | 42.3 | 1.00 | 1.00 | 0.03 |
Yes | 82 | 48.8 | 38 | 39.2 | 0.58 (0.32–1.05) | 0.41 (0.18–0.93) | |
Unknown* | 35 | 20.8 | 18 | 18.6 | |||
Employment | |||||||
No | 50 | 29.8 | 43 | 44.3 | 1.00 | ||
Yes | 75 | 44.6 | 36 | 37.1 | 0.56 (0.30–1.03) | ||
Unknown* | 43 | 25.6 | 18 | 18.6 | |||
HIV status | |||||||
Negative | 111 | 66.1 | 60 | 61.9 | 1.00 | ||
Positive | 19 | 11.3 | 7 | 7.2 | 0.68 (0.23–1.82) | ||
Unknown* | 38 | 22.6 | 30 | 30.9 | |||
History of latent TB | |||||||
No | 112 | 66.7 | 68 | 70.1 | 1.00 | ||
Yes | 27 | 16.1 | 13 | 13.4 | 0.79 (0.35–1.72) | ||
Unknown* | 29 | 17.3 | 16 | 16.5 | |||
Prior history of active TB | |||||||
No | 150 | 89.3 | 90 | 92.8 | 1.00 | ||
Yes | 10 | 6.0 | 4 | 4.1 | 0.67 (0.15–2.40) | ||
Unknown* | 8 | 4.8 | 3 | 3.1 | |||
Sputum AFB smear result | |||||||
Negative | 80 | 47.6 | 52 | 53.6 | 1.00 | ||
Positive | 61 | 36.3 | 33 | 34.0 | 0.83 (0.46–1.49) | ||
Unknown* | 27 | 16.1 | 12 | 12.4 | |||
Site of disease | |||||||
Extrapulmonary | 37 | 22.0 | 22 | 22.7 | 1.00 | ||
Pulmonary | 131 | 78.0 | 75 | 77.3 | 0.96 (0.51–1.85) | ||
History of drug use | |||||||
No | 158 | 94.0 | 89 | 91.8 | 1.00 | ||
Yes | 5 | 3.0 | 5 | 5.2 | 1.78 (0.40–7.92) | ||
Unknown* | 5 | 3.0 | 3 | 3.1 | |||
Excessive alcohol use | |||||||
No | 126 | 75.0 | 63 | 64.9 | 1.00 | ||
Yes | 33 | 19.6 | 26 | 26.8 | 1.58 (0.83–2.98) | ||
Unknown* | 9 | 5.4 | 8 | 8.2 | |||
Underlying medical condition | |||||||
No | 123 | 73.2 | 69 | 71.1 | 1.00 | ||
Yes | 45 | 26.8 | 28 | 28.9 | 1.11 (0.61–2.00) | ||
Drug resistance | |||||||
No | 134 | 79.8 | 87 | 89.7 | 1.00 | ||
Yes | 34 | 20.2 | 9 | 9.3 | 0.40 (0.16–0.91) | ||
Unknown* | 0 | 0.0 | 1 | 1.0 | |||
Treatment outcome | |||||||
Completed treatment | 134 | 79.8 | 79 | 81.4 | 1.00 | ||
Died before treatment completed | 17 | 10.1 | 4 | 4.1 | 0.40 (0.13–1.23) | ||
Lost to follow-up | 11 | 6.5 | 8 | 8.2 | 1.23 (0.48–3.20) | ||
Unknown* | 6 | 3.6 | 6 | 6.2 |
*, Not included in χ2 and OR calculations.